Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLAROTM (ixazomib), the First Oral Proteasome Inhibitor, for Use in Patients with Multiple Myeloma

Takeda
Posted on: 19 Sep 16

If authorised, ixazomib will provide a new treatment option for European patients with multiple myeloma who have received at least one prior therapy

 

Opinion based on TOURMALINE-MM1 trial, in which ixazomib plus lenalidomide and dexamethasone demonstrated six month improvement in progression-free survival versus the placebo regimen

 

Takeda UK, High Wycombe, UK, Friday 16th September 2016 – Takeda UK Limited announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the conditional approval of ixazomib capsules in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. If the European Commission ratifies the CHMP’s opinion and authorisation is granted, ixazomib will be the first oral proteasome inhibitor approved for use across the European Economic Area, which includes the 28 member states of the European Union as well as Norway, Liechtenstein and Iceland.

 

“This is great news and a very positive development for myeloma patients in Europe,” said Eric Low, Chief Executive, Myeloma UK, and Board Member, Myeloma Patients Europe. “The improvement in progression free survival in this difficult-to-treat stage of myeloma is significant. In addition to ixazomib’s efficacy in this relapsed and/or refractory group of patients, its manageable safety profile and oral administration makes ixazomib a very welcome new treatment option for this serious and complex cancer. It is important that attention is now turned in earnest to the Health Technology Assessment bodies to ensure their approval of ixazomib.’’

 

Data from the pivotal Phase 3 trial TOURMALINE-MM1 demonstrate that the addition of ixazomib to lenalidomide and dexamethasone provides a significant improvement in progression-free survival when compared to placebo plus lenalidomide and dexamethasone in relapsed / refractory multiple myeloma patients who have received one to three prior therapies.[i] Patients continue to be treated to progression in the trial, with additional evaluations planned for long-term outcomes such as overall survival.

 

UK clinicians available for interview:

·         Prof. Graham Jackson, Freeman Hospital, Newcastle

·         Dr Karthik Ramasamy, Churchill Hospital, Oxford

·         Dr Matthew Jenner, University Hospital Southampton

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 19/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.